Cargando…

Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy

Background: Although disopyramide has been widely used to reduce left ventricular outflow obstruction (LVOTO) and to improve symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM), its use in real world as well as patient characteristics associated with a positive treatment respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maurizi, Niccolò, Chiriatti, Chiara, Fumagalli, Carlo, Targetti, Mattia, Passantino, Silvia, Antiochos, Panagiotis, Skalidis, Ioannis, Chiti, Chiara, Biagioni, Giulia, Tomberli, Alessia, Giovani, Sara, Coppini, Raffaele, Cecchi, Franco, Olivotto, Iacopo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095445/ https://www.ncbi.nlm.nih.gov/pubmed/37048808 http://dx.doi.org/10.3390/jcm12072725

Ejemplares similares

Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study
por: Coppini, Raffaele, et al.
Publicado: (2019)

Disopyramide for Hypertrophic Cardiomyopathy
por: Sanchez-Nadales, Alejandro, et al.
Publicado: (2019)

Hypertrophic cardiomyopathy: The need for randomized trials
por: Olivotto, Iacopo, et al.
Publicado: (2013)

Use of Smartphone-operated ECG for home ECG surveillance in COVID-19 patients
por: Maurizi, Niccolò, et al.
Publicado: (2021)

Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations
por: Coppini, Raffaele, et al.
Publicado: (2014)

Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients
por: Adler, Arnon, et al.
Publicado: (2017)

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside
por: Palandri, Chiara, et al.
Publicado: (2022)

Clinical and molecular classification of cardiomyopathies
por: Cecchi, Franco, et al.
Publicado: (2012)

Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions
por: Girolami, Francesca, et al.
Publicado: (2023)

Genetic characterization of juvenile sudden cardiac arrest and death in Tuscany: The ToRSADE registry
por: Girolami, Francesca, et al.
Publicado: (2022)

Microvascular Dysfunction in Hypertrophic Cardiomyopathy
por: Pelliccia, Francesco, et al.
Publicado: (2022)

Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center
por: Mazzarotto, Francesco, et al.
Publicado: (2018)

Emerging Medical Treatment for Hypertrophic Cardiomyopathy
por: Argirò, Alessia, et al.
Publicado: (2021)

The Clinical Development of Disopyramide
por: Ankier, S. I.
Publicado: (1976)

Stage-specific therapy for hypertrophic cardiomyopathy
por: Argirò, Alessia, et al.
Publicado: (2023)

Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy
por: Bernardini, Andrea, et al.
Publicado: (2023)

Genotype-Driven Pathogenesis of Atrial Fibrillation in Hypertrophic Cardiomyopathy: The Case of Different TNNT2 Mutations
por: Pioner, Josè Manuel, et al.
Publicado: (2022)

Impact of Short-Acting Disopyramide on Left Ventricular Mechanics Evaluated by Strain Analysis in Patients with Hypertrophic Obstructive Cardiomyopathy
por: Yedidya, Idit, et al.
Publicado: (2022)

T-tubule remodeling in human hypertrophic cardiomyopathy
por: Vitale, Giulia, et al.
Publicado: (2020)

Late sodium current inhibitors to treat exercise‐induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium
por: Ferrantini, Cecilia, et al.
Publicado: (2018)

The Role of Disopyramide after Myocardial Infarction
por: Jones, M. B. S.
Publicado: (1976)

Paradoxical prolongation of QT interval during exercise in patients with hypertrophic cardiomyopathy: cellular mechanisms and implications for diastolic function
por: Coppini, Raffaele, et al.
Publicado: (2022)

Doctor-patient care relationship in genetic cardiomyopathies: An exploratory study on clinical consultations
por: Fioretti, Chiara, et al.
Publicado: (2020)

Comprehensive Risk Management in Arrhythmogenic Cardiomyopathy Associated With Autosomal Dominant Carvajal Syndrome: Protecting Families
por: De Gregorio, Maria Grazia, et al.
Publicado: (2020)

Acute cardiac failure and hepatic ischemia induced by disopyramide phosphate.
por: Scheinman, S. J., et al.
Publicado: (1980)

Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?
por: Jaafar, Nawel, et al.
Publicado: (2015)

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter
por: Masri, Ahmad, et al.
Publicado: (2022)

INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan)
por: Olivotto, Iacopo, et al.
Publicado: (2015)

Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy
por: Tafelmeier, Maria, et al.
Publicado: (2020)

Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy
por: Lombardi, Maria, et al.
Publicado: (2021)

Ion Channel Impairment and Myofilament Ca(2+) Sensitization: Two Parallel Mechanisms Underlying Arrhythmogenesis in Hypertrophic Cardiomyopathy
por: Santini, Lorenzo, et al.
Publicado: (2021)

Altered Ca(2+) and Na(+) Homeostasis in Human Hypertrophic Cardiomyopathy: Implications for Arrhythmogenesis
por: Coppini, Raffaele, et al.
Publicado: (2018)

Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models
por: Ferrantini, Cecilia, et al.
Publicado: (2017)

Mitochondrial Energetics and Ca(2+)-Activated ATPase in Obstructive Hypertrophic Cardiomyopathy
por: Lombardi, Maria, et al.
Publicado: (2020)

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy
por: El-Hamamsy, Ismail, et al.
Publicado: (2012)

Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry
por: Canepa, Marco, et al.
Publicado: (2020)

Feasibility of a Combined Mobile-Health Electrocardiographic and Rapid Diagnostic Test Screening for Chagas-Related Cardiac Alterations
por: Spinicci, Michele, et al.
Publicado: (2021)

Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive Cardiomyopathy
por: Pelliccia, F., et al.
Publicado: (2021)

Late gadolinium enhancement score (LGE-Score) for prediction of extensive late gadolinium enhancement in hypertrophic cardiomyopathy
por: Chan, Raymond H, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9bir9eh5pchi3c0f06feb9lva9